{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:46:26Z","timestamp":1793126786975,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"DOI":"10.1186\/s12890-024-03414-x","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T12:52:08Z","timestamp":1734353528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The assessment of dupilumab in children with moderate-to-severe asthma and comorbid type 2 inflammatory diseases"],"prefix":"10.1186","volume":"24","author":[{"given":"Tingting","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaping","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genquan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gen","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,16]]},"reference":[{"issue":"2","key":"3414_CR1","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157\u201371.","journal-title":"N Engl J Med"},{"key":"3414_CR2","doi-asserted-by":"crossref","unstructured":"Serebrisky D, Wiznia A. Pediatric Asthma: A Global Epidemic. Annals Global Health 2019, 85(1).","DOI":"10.5334\/aogh.2416"},{"issue":"4","key":"3414_CR3","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.jaip.2017.04.031","volume":"5","author":"SK Ramratnam","year":"2017","unstructured":"Ramratnam SK, Bacharier LB, Guilbert TW. Severe asthma in children. J Allergy Clin Immunol Pract. 2017;5(4):889\u201398.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"24","key":"3414_CR4","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1056\/NEJMoa2106567","volume":"385","author":"LB Bacharier","year":"2021","unstructured":"Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Jain N, Sher LD, Mao X, Liu D, et al. Dupilumab in children with uncontrolled moderate-to-severe asthma. N Engl J Med. 2021;385(24):2230\u201340.","journal-title":"N Engl J Med"},{"issue":"19","key":"3414_CR5","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1056\/NEJMoa1513737","volume":"374","author":"MJ McGeachie","year":"2016","unstructured":"McGeachie MJ, Yates KP, Zhou X, Guo F, Sternberg AL, Van Natta ML, Wise RA, Szefler SJ, Sharma S, Kho AT, et al. Patterns of growth and decline in lung function in Persistent Childhood Asthma. N Engl J Med. 2016;374(19):1842\u201352.","journal-title":"N Engl J Med"},{"issue":"1","key":"3414_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12931-018-0890-0","volume":"19","author":"LP Hayden","year":"2018","unstructured":"Hayden LP, Cho MH, Raby BA, Beaty TH, Silverman EK, Hersh CP. Childhood asthma is associated with COPD and known asthma variants in COPDGene: a genome-wide association study. Respir Res. 2018;19(1):209.","journal-title":"Respir Res"},{"issue":"5","key":"3414_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.3892\/etm.2021.10698","volume":"22","author":"AP Fildan","year":"2021","unstructured":"Fildan AP, Rajnoveanu RM, Cirjaliu R, Pohrib I, Tudorache E, Ilie AC, Oancea C, Tofolean D. Biological therapies targeting the type 2 inflammatory pathway in severe asthma (review). Experimental Therapeutic Med. 2021;22(5):1263.","journal-title":"Experimental Therapeutic Med"},{"issue":"7","key":"3414_CR8","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/cea.13954","volume":"51","author":"JD Hamilton","year":"2021","unstructured":"Hamilton JD, Harel S, Swanson BN, Brian W, Chen Z, Rice MS, Amin N, Ardeleanu M, Radin A, Shumel B, et al. Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases. Clin Experimental Allergy: J Br Soc Allergy Clin Immunol. 2021;51(7):915\u201331.","journal-title":"Clin Experimental Allergy: J Br Soc Allergy Clin Immunol"},{"key":"3414_CR9","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2024 (https:\/\/ginasthma.org\/wp-content\/uploads\/ 2024\/05\/ GINA \u2013\u20092024-Strategy-Report-24_05_22_WMS.pdf)."},{"key":"3414_CR10","unstructured":"Global initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. [2022-05-25]. https:\/\/ginasthma.org\/wp-content\/ uploads \/2022\/05\/GINA-Main-Report-2022-FINAL2205-03-WMS. pdf."},{"key":"3414_CR11","unstructured":"DUPIXENT\u00ae (dupilumab). Highlights of Prescribing Information. US Food and Drug Administration. Accessed October 24. 2022. https:\/\/www.regeneron.com\/sites\/default\/files\/Dupixent_FPI.pdf"},{"key":"3414_CR12","unstructured":"DUPIXENT\u00ae (dupilumab). Summary of Product Characteristics. European Medicines Agency.Accessed October 24. 2022. https:\/\/www.ema.europa.eu\/en\/documents\/productinformation\/dupixent-epar-product-information_en.pdf"},{"issue":"1","key":"3414_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.anai.2023.03.014","volume":"131","author":"DJ Jackson","year":"2023","unstructured":"Jackson DJ, Bacharier LB, Phipatanakul W, Sher L, Domingo C, Papadopoulos N, Modena B, Li N, Xia C, Kamal MA, et al. Dupilumab pharmacokinetics and effect on type 2 biomarkers in children with moderate-to-severe asthma. Annals Allergy Asthma Immunol. 2023;131(1):44\u2013e5144.","journal-title":"Annals Allergy Asthma Immunol"},{"issue":"8","key":"3414_CR14","doi-asserted-by":"publisher","first-page":"2157","DOI":"10.1111\/all.15743","volume":"78","author":"NG Papadopoulos","year":"2023","unstructured":"Papadopoulos NG, Szefler SJ, Bacharier LB, Maspero JF, Domingo C, Fiocchi A, Lee JK, Daizadeh N, Lederer DJ, Hardin M, et al. Assessment of dupilumab in children with moderate-to-severe type 2 asthma with or without evidence of allergic asthma. Allergy. 2023;78(8):2157\u201367.","journal-title":"Allergy"},{"issue":"3","key":"3414_CR15","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1007\/s12325-022-02399-5","volume":"40","author":"R Gall","year":"2023","unstructured":"Gall R, Jain N, Soong W, Settipane RA, Xia C, Zhang Y, Haselkorn T, Jacob-Nara JA, Siddiqui S. Dupilumab-treated patients with asthma in the Real World: the RAPID Global Registry. Adv Therapy. 2023;40(3):1292\u20138.","journal-title":"Adv Therapy"},{"issue":"11","key":"3414_CR16","doi-asserted-by":"publisher","first-page":"300060522113368","DOI":"10.1177\/03000605221133689","volume":"50","author":"F Menzella","year":"2022","unstructured":"Menzella F, Ballarin A, Sartor M, Floriani AF, Corsi L, Dartora C, Tonin S, Romagnoli M. Comparison between clinical trials and real-world evidence studies on biologics for severe asthma. J Int Med Res. 2022;50(11):3000605221133689.","journal-title":"J Int Med Res"},{"issue":"3","key":"3414_CR17","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1111\/jdv.15979","volume":"34","author":"R Cheng","year":"2020","unstructured":"Cheng R, Zhang H, Zong W, Tang J, Han X, Zhang L, Zhang X, Gu H, Shu Y, Peng G, et al. Development and validation of new diagnostic criteria for atopic dermatitis in children of China. J Eur Acad Dermatol Venereol. 2020;34(3):542\u20138.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"3414_CR18","unstructured":"[Guideline for diagnosis and treatment of pediatric allergic rhinitis. (2022, revision)]. Zhonghua er bi yan hou tou jing wai ke za zhi\u2009=\u2009Chinese journal of otorhinolaryngology head and neck surgery 2022, 57(4):392\u2013404."},{"issue":"Supple 4","key":"3414_CR19","first-page":"S375371","volume":"146","author":"M Miller","year":"2020","unstructured":"Miller M, Davis K. Dupilumab Efficacy in patients with uncontrolled, moderate-to-severe allergic asthma. Pediatrics. 2020;146(Supple 4):S375371\u2013375.","journal-title":"Pediatrics"},{"issue":"2","key":"3414_CR20","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/ACI.0000000000000348","volume":"17","author":"MJ McGeachie","year":"2017","unstructured":"McGeachie MJ. Childhood asthma is a risk factor for the development of chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol. 2017;17(2):104\u20139.","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"4","key":"3414_CR21","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jaip.2023.12.006","volume":"12","author":"LB Bacharier","year":"2024","unstructured":"Bacharier LB, Guilbert TW, Katelaris CH, Deschildre A, Phipatanakul W, Liu D, Altincatal A, Mannent LP, Amin N, Laws E, et al. Dupilumab improves lung function parameters in Pediatric Type 2 Asthma: VOYAGE study. J Allergy Clin Immunology-In Pract. 2024;12(4):948\u201359.","journal-title":"J Allergy Clin Immunology-In Pract"},{"issue":"2","key":"3414_CR22","doi-asserted-by":"publisher","first-page":"Ab18","DOI":"10.1016\/j.jaci.2022.12.059","volume":"151","author":"J Maspero","year":"2023","unstructured":"Maspero J, Fiocchi A, Deschildre A, Bacharier L, Altincatal A, Laws E, Lederer D, Akinlade B, Hardin M. Consistent efficacy of Dupilumab in Children (6\u201311 years) with type 2 Asthma regardless of baseline demographics and Disease characteristics. J Allergy Clin Immunol. 2023;151(2):Ab18.","journal-title":"J Allergy Clin Immunol"},{"issue":"S5","key":"3414_CR23","first-page":"18","volume":"52","author":"P53: DUPILUMAB LEADS TO CLINICAL ASTHMA REMISSION INDICATIVE OF COMPREHENSIVE IMPROVEMENT IN PATIENTS WITH ASTHMA: RESULTS FROM THE LIBERTY ASTHMA QUEST AND TRAVERSE STUDIES","year":"2022","unstructured":"P53: DUPILUMAB LEADS TO CLINICAL ASTHMA REMISSION INDICATIVE OF COMPREHENSIVE IMPROVEMENT IN PATIENTS WITH ASTHMA: RESULTS FROM THE LIBERTY ASTHMA QUEST AND TRAVERSE STUDIES. Intern Med J. 2022;52(S5):18\u201318.","journal-title":"Intern Med J"},{"issue":"3","key":"3414_CR24","doi-asserted-by":"publisher","first-page":"Ab141","DOI":"10.1016\/j.jaad.2021.06.577","volume":"85","author":"A Paller","year":"2021","unstructured":"Paller A, Weidinger S, Cork M, Marcoux D, Katoh N, Zhang H, Rossi A, Shumel B, Zhang A, Prescilla R, et al. 27394 dupilumab provides clinically meaningful improvement in atopic dermatitis (AD) signs, symptoms, and quality of life in children with severe AD: results from the LIBERTY AD PEDS phase 3 clinical trial. J Am Acad Dermatol. 2021;85(3):Ab141.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"3414_CR25","doi-asserted-by":"publisher","first-page":"Ab32","DOI":"10.1016\/j.jaci.2020.12.151","volume":"147","author":"M Boguniewicz","year":"2021","unstructured":"Boguniewicz M, Sher L, Paller A, Siegfried E, Chen Z, Prescilla R, Shumel B. Dupilumab improves signs and symptoms of severe atopic dermatitis in children aged 6\u201311 years with and without Comorbid Asthma. J Allergy Clin Immunol. 2021;147(2):Ab32.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"3414_CR26","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.anai.2021.08.097","volume":"127","author":"L Bacharier","year":"2021","unstructured":"Bacharier L, Maspero J, Katelaris C, Fiocchi A, Liu D, Lederer D, Hardin M. P068 DUPILUMAB REDUCES BIOMARKERS OF TYPE 2 INFLAMMATION IN CHILDREN WITH UNCONTROLLED, MODERATE-TO-SEVERE ASTHMA. Annals Allergy Asthma Immunol. 2021;127(5):S33.","journal-title":"Annals Allergy Asthma Immunol"},{"issue":"6","key":"3414_CR27","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1080\/07853890701449354","volume":"39","author":"LK Poulsen","year":"2007","unstructured":"Poulsen LK, Hummelshoj L. Triggers of IgE class switching and allergy development. Ann Med. 2007;39(6):440\u201356.","journal-title":"Ann Med"},{"key":"3414_CR28","doi-asserted-by":"crossref","unstructured":"Wechsler ME, Munitz A, Ackerman SJ, Drake MG, Jackson DJ, Wardlaw AJ, Dougan SK, Berdnikovs S, Schleich F, Matucci A et al. Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo clinic proceedings 2021, 96(10):2694\u20132707.","DOI":"10.1016\/j.mayocp.2021.04.025"},{"issue":"26","key":"3414_CR29","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","volume":"378","author":"M Castro","year":"2018","unstructured":"Castro M, Corren J, Pavord ID, Maspero J, Wenzel S, Rabe KF, Busse WW, Ford L, Sher L, FitzGerald JM, et al. Dupilumab Efficacy and Safety in Moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486\u201396.","journal-title":"N Engl J Med"},{"issue":"5","key":"3414_CR30","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/all.14151","volume":"75","author":"A Le Floc\u2019h","year":"2020","unstructured":"Le Floc\u2019h A, Allinne J, Nagashima K, Scott G, Birchard D, Asrat S, Bai Y, Lim WK, Martin J, Huang T, et al. Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R\u03b1 antibody, is required to broadly inhibit type 2 inflammation. Allergy. 2020;75(5):1188\u2013204.","journal-title":"Allergy"},{"issue":"1","key":"3414_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.alit.2022.07.008","volume":"72","author":"Y Tohda","year":"2023","unstructured":"Tohda Y, Nakamura Y, Fujisawa T, Ebisawa M, Msihid J, Djandji M, Ortiz B, Jacob-Nara JA, Deniz Y, Rowe PJ, et al. Efficacy of dupilumab in patients with uncontrolled, moderate-to-severe asthma recruited from Japanese centers in the phase 3 LIBERTY ASTHMA TRAVERSE study. Allergology Int. 2023;72(1):89\u201399.","journal-title":"Allergology Int"},{"issue":"7","key":"3414_CR32","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/cea.13614","volume":"50","author":"C Dupin","year":"2020","unstructured":"Dupin C, Belhadi D, Guilleminault L, Gamez AS, Berger P, De Blay F, Bonniaud P, Leroyer C, Mahay G, Girodet PO, et al. Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. Clin Experimental Allergy: J Br Soc Allergy Clin Immunol. 2020;50(7):789\u201398.","journal-title":"Clin Experimental Allergy: J Br Soc Allergy Clin Immunol"},{"issue":"3","key":"3414_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s00281-021-00857-w","volume":"43","author":"J Catherine","year":"2021","unstructured":"Catherine J, Roufosse F. What does elevated TARC\/CCL17 expression tell us about eosinophilic disorders? Semin Immunopathol. 2021;43(3):439\u201358.","journal-title":"Semin Immunopathol"},{"issue":"10351","key":"3414_CR34","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/S0140-6736(22)01198-9","volume":"400","author":"DJ Jackson","year":"2022","unstructured":"Jackson DJ, Bacharier LB, Gergen PJ, Gagalis L, Calatroni A, Wellford S, Gill MA, Stokes J, Liu AH, Gruchalla RS, et al. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet. 2022;400(10351):502\u201311.","journal-title":"Lancet"},{"key":"3414_CR35","doi-asserted-by":"crossref","unstructured":"Corren J, Kavati A, Ortiz B, Colby JA, Ruiz K, Maiese BA, Cadarette SM, Panettieri RA. Efficacy and safety of omalizumab in children and adolescents with moderate-to-severe asthma: A systematic literature review. Allergy and asthma proceedings 2017, 38(4):250\u2013263.","DOI":"10.2500\/aap.2017.38.4067"},{"issue":"3","key":"3414_CR36","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1016\/j.jaci.2019.10.037","volume":"145","author":"ML Manson","year":"2020","unstructured":"Manson ML, S\u00e4fholm J, James A, Johnsson AK, Bergman P, Al-Ameri M, Orre AC, K\u00e4rrman-M\u00e5rdh C, Dahl\u00e9n SE, Adner M. IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. J Allergy Clin Immunol. 2020;145(3):808\u2013e817802.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"3414_CR37","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2213-2600(23)00303-X","volume":"12","author":"LB Bacharier","year":"2024","unstructured":"Bacharier LB, Maspero JF, Katelaris CH, Fiocchi AG, Gagnon R, de Mir I, Guilbert TW, Jackson DJ, Staudinger HW, Laws E, et al. Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study. Lancet Respiratory Med. 2024;12(1):45\u201354.","journal-title":"Lancet Respiratory Med"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03414-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-024-03414-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-024-03414-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T13:04:08Z","timestamp":1734354248000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-024-03414-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3414"],"URL":"https:\/\/doi.org\/10.1186\/s12890-024-03414-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,16]]},"assertion":[{"value":"4 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Clinical Trial Number: NCT02948959(Registration Date:2016-10-31) which is retrospectively registered. This study was conducted in accordance with the Declaration of Helsinki and approved by the ethics committee of the Guangzhou Women and Children\u2019s Medical Center, Guangzhou Medical University, Ethics number: [2024]162A01.Written informed consent to participate in this study was obtained from their parents\/guardians. The datasets generated and\/or analyzed during the current study are not publicly available due individual privacy of patients could be compromised, but are available from the corresponding author on reasonable request.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"607"}}